Out of stock

The purpose of this letter to the editor is to provide a brief clinical reference for rough equivalency of approved and commonly used GLP‐1 ± GIP RAs for A1c and weight reduction in people with type 2 diabetes.

The purpose of this letter to the editor is to provide a brief clinical reference for rough equivalency of approved and commonly used GLP-1 ± GIP RAs for A1c and weight reduction in people with type 2 diabetes. 2 MATERIALS AND METHODS All data are taken from pivotal trials included in the FDA-approved prescribing information.
Out of stock

The purpose of this letter to the editor is to provide a brief clinical reference for rough equivalency of approved and commonly used GLP-1 ± GIP RAs for A1c and weight reduction in people with type 2 diabetes.
During this time of global shortage of glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) ± glucose‐dependent insulinotropic polypeptide (GIP) RA therapies, this research letter offers a quick clinical reference of rough equivalency between GLP‐1 ± GIP RA for A1c and body weight reduction in people with type 2 diabetes.

Out of stock
The purpose of this letter to the editor is to provide a brief clinical reference for rough equivalency of approved and commonly used GLP‐1 ± GIP RAs for A1c and weight reduction in people with type 2 diabetes.
A quick clinical reference of rough equivalency between GLP‐1 ± GIP RA for A1c and body weight reduction in people with type 2 diabetes is offered. Highlights Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon. During this time of global shortage of glucagon‐like peptide‐1 ...

Out of stock
Out of stock : A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 ( GLP ‐1) ± glucose‐dependent insulinotropic polypeptide ( GIP ) receptor agonists for A1c and ...
Out of stock : A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes Journal of Diabetes ( IF3.0 ) Pub Date : 2023-11-20, DOI: 10.1111/1753-0407.13505 Leigh Perreault 1 , Bryan C Bergman 1

Leigh Perreault
Out of stock : A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes.



